Creative Scientist, Inc. offers a client-specific 96-well skin/dermal equivalent platform for concentration-response screening of compounds affecting hair growth. Utilizing human keratinocytes, hair follicle bulge stem cells, and dermal papilla-like cells, it provides scalable and biologically relevant assessments.
Creative Scientist, Inc. has developed a client-specific platform designed for the quantitative screening of compounds influencing hair growth-associated biology. This innovative solution employs a 96-well skin/dermal equivalent system built from human keratinocytes, hair follicle bulge stem cells, and dermal papilla-like cells. The platform is tailored for concentration-response analysis, providing a scalable and biologically relevant method to evaluate compounds that affect hair growth processes. This system enables parallel assessments of epithelial stem-cell fate and mesenchymal support-cell fate, crucial for understanding hair biology.
Key features:
This technology is currently at Technology Readiness Level 2, indicating that the core concept and components have been established in a lab setting. A 12-month proof-of-concept program is planned to further validate and optimize the assay configurations, aiming to deliver a comprehensive dataset and workflow for next-stage expansion.
Creative Scientist, Inc. is a biotechnology company based in Durham, North Carolina, that specializes in providing contract research services. The company offers a range of advanced scientific solutions, including cell-based assays, organoid generation, high-content imaging, and high-throughput electroporation, specifically designed to support translational research and drug development efforts.
Founded in 2010 by Alexander Kinev, the company focuses on assisting researchers in navigating complex biological models and drug discovery workflows. By providing specialized technical expertise and advanced experimental platforms, Creative Scientist, Inc. helps partners accelerate their development timelines and improve the precision of their preclinical investigations.